US, Korea Join Hands On Precision Meds, MERS Vaccines
This article was originally published in PharmAsia News
South Korea is continuing to step up its fight against infectious diseases. Following the Seoul Declaration after the Global Health Security Agenda meeting in the country last month, it has now reached an agreement with the US NIH to cooperate for the development of precision medicines and MERS vaccines and therapies.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.